NASDAQ: PAYS · Trade & Services · 3 alerts · CIK 1496443
Share price
$9.54Close, Nov 16
Market cap
$542M
Shares outstanding
56.85MLatest SEC cover page
Sector
Trade & Services
Industry
Services-Business Services, NECSIC 7389
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Paysign, Inc. filings on SEC EDGAR ↗
Paysign, Inc. reported significant growth for the nine months ended September 30, 2026, with total revenues increasing to $87.1 million compared to $59.3 million in the prior year, driven largely by a doubling of Pharma industry revenue. Net income for the nine-month period rose to $18.9 million, up from $6.2 million in 2025, reflecting improved operating leverage and higher interest income.
Paysign reported record third-quarter 2026 revenue of $30.8 million, a 43% increase year-over-year, driven by 110% growth in its Pharma patient affordability segment. The company's operating margin more than tripled to 23.8%, and GAAP net income rose to $6.74 million. Management raised full-year 2026 guidance for gross margin, net income, and Adjusted EBITDA while confirming its revenue outlook.
Term
Q3 2026
“This was a strong quarter, with patient affordability continuing to compound. We expanded to 167 active programs and increased the quarterly revenue per program by approximately 32% to $99,524. As that business becomes a larger share of our total revenue, we’re seeing gross margin and operating margin expand together, which is translating into higher Adjusted EBITDA.”
Mark Newcomer, President and CEO
“Patient affordability is driving our business, and we are seeing demand and momentum continue to build. Plasma remains an important part of our business, and our experience as one of the leading processors in the industry has given us the insights to understand the challenges plasma centers face.”